JP2016501528A5 - - Google Patents

Download PDF

Info

Publication number
JP2016501528A5
JP2016501528A5 JP2015546782A JP2015546782A JP2016501528A5 JP 2016501528 A5 JP2016501528 A5 JP 2016501528A5 JP 2015546782 A JP2015546782 A JP 2015546782A JP 2015546782 A JP2015546782 A JP 2015546782A JP 2016501528 A5 JP2016501528 A5 JP 2016501528A5
Authority
JP
Japan
Prior art keywords
sequence
seq
viral particle
protein
isolated viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015546782A
Other languages
English (en)
Japanese (ja)
Other versions
JP6162818B2 (ja
JP2016501528A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2012/050893 external-priority patent/WO2014089668A1/en
Publication of JP2016501528A publication Critical patent/JP2016501528A/ja
Publication of JP2016501528A5 publication Critical patent/JP2016501528A5/ja
Application granted granted Critical
Publication of JP6162818B2 publication Critical patent/JP6162818B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015546782A 2012-12-12 2012-12-12 脳癌の治療のための組成物及び方法 Expired - Fee Related JP6162818B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2012/050893 WO2014089668A1 (en) 2012-12-12 2012-12-12 Compositions and methods for the treatment of brain cancers

Publications (3)

Publication Number Publication Date
JP2016501528A JP2016501528A (ja) 2016-01-21
JP2016501528A5 true JP2016501528A5 (enExample) 2016-03-03
JP6162818B2 JP6162818B2 (ja) 2017-07-12

Family

ID=50933623

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015546782A Expired - Fee Related JP6162818B2 (ja) 2012-12-12 2012-12-12 脳癌の治療のための組成物及び方法

Country Status (11)

Country Link
US (1) US20150307559A1 (enExample)
EP (1) EP2931880B1 (enExample)
JP (1) JP6162818B2 (enExample)
CN (1) CN105008524A (enExample)
AU (1) AU2012396787B9 (enExample)
BR (1) BR112015013669A2 (enExample)
CA (1) CA2894618A1 (enExample)
IL (1) IL239374B (enExample)
MX (1) MX366493B (enExample)
RU (1) RU2705244C2 (enExample)
WO (1) WO2014089668A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9045729B2 (en) 2009-12-10 2015-06-02 Ottawa Hospital Research Institute Oncolytic rhabdovirus
WO2012167382A1 (en) 2011-06-08 2012-12-13 Children's Hospital Of Eastern Ontario Research Institute Inc. Compositions and methods for glioblastoma treatment
WO2014127478A1 (en) 2013-02-21 2014-08-28 Children's Hospital Of Eastern Ontario Research Institute Inc. Vaccine composition
EP3624825A4 (en) * 2017-05-19 2021-03-10 Georgia State University Research Foundation, Inc. RECOMBINANT ONCOLYTIC VIRUS
PL3684786T3 (pl) * 2017-09-22 2024-12-16 Centre National De La Recherche Scientifique (Cnrs) Zmutowana glikoproteina wirusa pęcherzykowego zapalenia jamy ustnej
DE102018215551A1 (de) 2018-09-12 2020-03-12 Virolutions Biotech Gmbh Verfahren zur Herstellung eines antitumoralen Arenavirus sowie Arenavirusmutanten
CN112442114A (zh) * 2019-08-29 2021-03-05 渥太华Hdl药物研发公司 一种多肽及其应用
CA3207359A1 (en) 2021-02-05 2022-08-11 Cecile Chartier-Courtaud Adjuvant therapy for cancer
US12440564B2 (en) 2023-09-25 2025-10-14 Kelonia Therapeutics, Inc. Compositions for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9307501A (en) * 2000-09-22 2002-04-02 Virxsys Improved conditionally replicating vectors, methods for their production and use
CA2921063C (en) * 2006-09-15 2020-01-28 Ottawa Hospital Research Institute Oncolytic rhabdovirus
DE102008050860A1 (de) 2008-10-08 2010-04-15 Dorothee Von Laer LCMV-GP-VSV-Pseudotypvektoren und tumorinfiltrierende Virenproduzentenzellen zur Therapie von Tumoren

Similar Documents

Publication Publication Date Title
JP2016501528A5 (enExample)
Araste et al. Peptide-based targeted therapeutics: Focus on cancer treatment
RU2015128078A (ru) Композиции и способы лечения рака мозга
Resnier et al. A review of the current status of siRNA nanomedicines in the treatment of cancer
Ibraheem et al. Administration strategies for proteins and peptides
Vecsernyés et al. Cyclodextrins, blood–brain barrier, and treatment of neurological diseases
JP2015518818A5 (enExample)
JP2014512171A5 (enExample)
JP2017031213A5 (enExample)
JP2013067645A5 (enExample)
WO2015024667A8 (en) Method for increasing expression of rna-encoded proteins
JP2016526531A5 (enExample)
JP2015514115A5 (enExample)
JP2013541583A5 (enExample)
SI2823048T1 (en) A new drug delivery system based on JCV-VLP
RU2012108144A (ru) Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами
CN111905101A (zh) 一种cd47抗体联合il-6细胞因子药在肿瘤治疗中的应用及验证其治疗肿瘤的方法
JP2017502058A5 (enExample)
JP2012517459A5 (enExample)
FI3919060T3 (fi) Ecopipam touretten oireyhtymän hoitoon
Hegde et al. To market, to market—2008
WO2013130672A3 (en) Improved cancer treatments and diagnostics
Maseda et al. Use of fidaxomicin through a nasogastric tube for the treatment of septic shock caused by Clostridium difficile infection in a patient with oral cancer admitted to the Surgical Critical Care Unit
JP2017508455A5 (enExample)
JP2014506563A5 (enExample)